基本信息
浏览量:137
职业迁徙
个人简介
I am a health informatics data scientist with interests in knowledge management applied to target and drug discovery, translational bioinformatics, target and drug repositioning, and health-record analytics. At AstraZeneca, I conceptually developed the lead-like approach for combinatorial chemistry and fragment-based drug discovery.
I evaluated over 500 bio-assays spanning hundreds of thousands of chemicals, and more than 50 target-based projects. This led to the identification of 7 NIH-designated chemical probes, including high-activity compounds for the G-protein coupled estrogen receptor (GPER), the formyl peptide receptors 1 and 2 (FPR, FPR2), the small GTP-ases Rac1 and Cdc42, and the ABCG2 efflux transporter, as well as a selective inhibitor for GLUT5, a fructose-only transporter. My in silico drug repositioning work at UNM led to anti-cancer clinical trials for Raltegravir (NCT01275183; as metnase inhibitor) and R-ketorolac (NCT01670799; as Rac1/Cdc42 inhibitor). I spent 4 years with Leslie Benet at UCSF (2007-2011) mining pharmacokinetics data, to understand the impact of drug metabolism and drug solubility on biodisponibility, drug safety and drug efficacy.
I evaluated over 500 bio-assays spanning hundreds of thousands of chemicals, and more than 50 target-based projects. This led to the identification of 7 NIH-designated chemical probes, including high-activity compounds for the G-protein coupled estrogen receptor (GPER), the formyl peptide receptors 1 and 2 (FPR, FPR2), the small GTP-ases Rac1 and Cdc42, and the ABCG2 efflux transporter, as well as a selective inhibitor for GLUT5, a fructose-only transporter. My in silico drug repositioning work at UNM led to anti-cancer clinical trials for Raltegravir (NCT01275183; as metnase inhibitor) and R-ketorolac (NCT01670799; as Rac1/Cdc42 inhibitor). I spent 4 years with Leslie Benet at UCSF (2007-2011) mining pharmacokinetics data, to understand the impact of drug metabolism and drug solubility on biodisponibility, drug safety and drug efficacy.
研究兴趣
论文共 387 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER RESEARCHno. 6 (2024)
BIOINFORMATICS ADVANCESno. 1 (2024)
Drug Discovery Todayno. 3 (2024): 103882-103882
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2024): 527-550
Nature reviews Drug discoveryno. 5 (2024): 330-330
Cancer Researchno. 6_Supplement (2024): 3535-3535
Ralph Steinkamp, George Tsitsiridis,Barbara Brauner,Corinna Montrone,Gisela Fobo,Goar Frishman, Sorin Avram,Tudor I Oprea,Andreas Ruepp
Nucleic acids research (2024)
ASPET 2024 Annual Meeting Abstract - Cancer Pharmacology (2024)
Tudor I Oprea, David Weininger
Journal of medicinal chemistryno. 20 (2024): 17935-17939
加载更多
作者统计
#Papers: 390
#Citation: 20115
H-Index: 70
G-Index: 136
Sociability: 7
Diversity: 3
Activity: 131
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn